Investments
34Portfolio Exits
5About Sham Innovation Sante
Sham Innovation Sante is an innovation capital vehicle-controlled and held by Sham, a mutual insurer specialized in risk management for health care, social welfare, and community health organizations. Advised by Turenne Capital, Sham Innovation Sante's mission is to support innovative businesses in the health care sector through the growth and development phases of their life cycle.

Want to inform investors similar to Sham Innovation Sante about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Sham Innovation Sante News
Mar 27, 2023
Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D Paris, Nice, and Chicago, 12 May 2022 – Therapixel, designer and supplier of MammoScreen® an Artificial Intelligence software reading aid for mammography, announces today fundraising of 15 M€ in series B. This operation was led by Crédit Mutuel Innovation and CapHorn, joined by Verve, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement. This fundraising will enable Therapixel to accelerate its commercial presence in the United States, launch more unique features for MammoScreen, and push even further the boundaries of its intelligent reading aid for mammography. Armed with two FDA regulatory clearances in the United Stated for both 2D and 3D (tomosynthesis) mammography, MammoScreen is already being deployed across large networks of breast cancer screening clinics. MammoScreen uses a unique score, MammoScreen Score™ to signal at a glance the level of suspicion of a mammogram. This makes it possible to confirm the lesions that are certain and to save precious time with a faster reading of benign cases. Radiologists can thus feel more confident in their decision and spend more time on difficult cases that require more attention. Matthieu Leclerc-Chalvet, Chief Executive Officer of Therapixel states: “We are very satisfied to close this new round of financing with investors active in the field of digital health. These funds will allow us to grow our American team with new sales and support people and to ramp up our commercial activities. With an already strong pipeline, Therapixel is poised for significant growth and will have a decisive impact on breast cancer screening.” Pierre Fillard, Chief Scientific and Technology Officer and Founder of Therapixel continues: “This is a major step for Therapixel and I am proud of the achievements of our teams in collaboration with radiologists partners. We will accelerate the launch of a new generation of AI that will allow women to benefit from an earlier detection with less anxiety and radiologists to be assisted in the ever-growing demand for imaging. We will also advance the regulatory and clinical developments that will solidify our leading position as the AI solution of choice for radiologists reading mammography”. With this new round, Therapixel has raised more than 20 M€ since its founding in 2013. The following council and advisor helped with this round: Legal counsel: JonesDay – Renaud Bonnet Financial advisors: Fraser Finance – Olivier Koechlin and Deborah Herst Press contacts: Aurélie Blanchard-Massoni (Omnes Capital) aurelie.blanchard-massoni@www-rec.omnescapital.com Valérie Roché-Melin (Région Sud Investissement) – v.roche@regionsudinvestissement.com About : Therapixel is a French company specialized in the design and commercialization of AI-powered medical imaging software, with the goal of delivering pertinent information at the right time to healthcare professionals. Winner of the Digital Mammography DREAM Challenge in 2017, the global competition on breast cancer detection with AI, Therapixel has developed MammoScreen®, a software that helps with the interpretation of screening 2D and 3D mammograms. With MammoScreen, even experienced radiologists can improve their performance, feel more confident in their judgment, and reassure women quicker. Find more at www.mammoscreen.com
Sham Innovation Sante Investments
34 Investments
Sham Innovation Sante has made 34 investments. Their latest investment was in Amolyt Pharma as part of their Series C on January 1, 2023.

Sham Innovation Sante Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/6/2023 | Series C | Amolyt Pharma | $138.38M | No | Andera Partners, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, EQT Life Sciences, ICG, InnoBio, Kurma Partners, Mass General Brigham Ventures, Novo Holdings, OrbiMed Advisors, Pontifax, Relyens, Sectoral Asset Management, Sham Innovation Sante, Sofinnova Partners, Tekla Capital Management, and Turenne Group | 8 |
10/14/2022 | Series A | Mablink Bioscience | $30.12M | No | 10 | |
5/12/2022 | Series B | Therapixel | $15.63M | Yes | 3 | |
5/10/2022 | Seed VC | |||||
5/10/2022 | Series A |
Date | 1/6/2023 | 10/14/2022 | 5/12/2022 | 5/10/2022 | 5/10/2022 |
---|---|---|---|---|---|
Round | Series C | Series A | Series B | Seed VC | Series A |
Company | Amolyt Pharma | Mablink Bioscience | Therapixel | ||
Amount | $138.38M | $30.12M | $15.63M | ||
New? | No | No | Yes | ||
Co-Investors | Andera Partners, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, EQT Life Sciences, ICG, InnoBio, Kurma Partners, Mass General Brigham Ventures, Novo Holdings, OrbiMed Advisors, Pontifax, Relyens, Sectoral Asset Management, Sham Innovation Sante, Sofinnova Partners, Tekla Capital Management, and Turenne Group | ||||
Sources | 8 | 10 | 3 |
Sham Innovation Sante Portfolio Exits
5 Portfolio Exits
Sham Innovation Sante has 5 portfolio exits. Their latest portfolio exit was CyberMDX on February 01, 2022.